Sequential combination of cisplatin with eugenol targets ovarian cancer stem cells through the Notch-Hes1 signalling pathway

Chemoresistance in ovarian cancer: exploiting cancer stem cell metabolism

(2018) Shan-Shan Li et al.   Journal of Gynecologic Oncology

miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer

(2018) Jing Sun et al.   ONCOGENE

Eugenol potentiates cisplatin anti-cancer activity through inhibition of ALDH-positive breast cancer stem cells and the NF-κB signaling pathway

(2017) Syed S. Islam et al.   MOLECULAR CARCINOGENESIS

Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism

(2016) Zhihong Ai et al.   CANCER LETTERS

Characterization of ovarian cancer cell lines as in vivo models for preclinical studies

(2016) Lidia Hernandez et al.   GYNECOLOGIC ONCOLOGY

Hes1: a key role in stemness, metastasis and multidrug resistance

(2015) Zi-Hao Liu et al.   CANCER BIOLOGY & THERAPY

Berberine Sensitizes Human Ovarian Cancer Cells to Cisplatin Through miR-93/PTEN/Akt Signaling Pathway

(2015) Qiaoyun Chen et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

Enhanced expression of DNA polymerase eta contributes to cisplatin resistance of ovarian cancer stem cells

(2015) Amit Kumar Srivastava et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The side population of ovarian cancer cells defines a heterogeneous compartment exhibiting stem cell characteristics

(2015) Maximilian Boesch et al.   Oncotarget

“Platinum resistant” ovarian cancer: What is it, who to treat and how to measure benefit?

(2014) Alison Davis et al.   GYNECOLOGIC ONCOLOGY

Evaluation of Cancer Stem Cell Markers CD133, CD44, CD24: Association with AKT Isoforms and Radiation Resistance in Colon Cancer Cells

(2014) Sara Häggblad Sahlberg et al.   PLoS One

Notch signaling in serous ovarian cancer

(2014) Jolijn W Groeneweg et al.   Journal of Ovarian Research

Eugenol triggers apoptosis in breast cancer cells through E2F1/survivin down-regulation

(2013) Ibtehaj Al-Sharif et al.   BMC CANCER

Evolving concepts in the management of drug resistant ovarian cancer: Dose dense chemotherapy and the reversal of clinical platinum resistance

(2012) David J. Pinato et al.   CANCER TREATMENT REVIEWS

Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance

(2012) K. Meirelles et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy

(2012) S. M. McAuliffe et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Stem Cell Pathways Contribute to Clinical Chemoresistance in Ovarian Cancer

(2011) A. D. Steg et al.   CLINICAL CANCER RESEARCH

Integrated genomic analyses of ovarian carcinoma

(2011) D. Bell et al.   NATURE

Targeting cancer stem cells by inhibiting Wnt, Notch and Hedgehog pathways

(2010) Naoko Takebe et al.   Nature Reviews Clinical Oncology

Hes genes and neurogenin regulate non-neural versus neural fate specification in the dorsal telencephalic midline

(2008) I. Imayoshi et al.   DEVELOPMENT

Sensitization of ovarian cancer cells to cisplatin by genistein: the role of NF-kappaB

(2008) Leigh A Solomon et al.   Journal of Ovarian Research